Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
View in:
PubMed
subject areas
Adult
Adult
B-Cell Activating Factor
B-Cell Activating Factor
Biomarkers
Biomarkers
Cross-Sectional Studies
Cross-Sectional Studies
Female
Female
Humans
Humans
Immunosuppressive Agents
Immunosuppressive Agents
Interferon Type I
Interferon Type I
Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic
Male
Male
Middle Aged
Middle Aged
Prospective Studies
Prospective Studies
RNA, Messenger
RNA, Messenger
Steroids
Steroids
Symptom Flare Up
Symptom Flare Up
Th17 Cells
Th17 Cells
Time Factors
Time Factors
Withholding Treatment
Withholding Treatment
authors with profiles
Joan Merrill
Judith A James
Aikaterini Thanou